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Despite all technical progress in modern diagnostic methods and treatment modalities of pheochromocytoma/paraganglioma, early 
consideration of the presence of these tumors remains the pivotal link towards the best possible outcome for patients. A timely diag-
nosis and proper treatment can prevent the wide variety of potentially catastrophic cardiovascular complications. Modern biochemi-
cal testing should include tests that offer the best available diagnostic performance, measurements of metanephrines and 3-methoxy-
tyramine in plasma or urine. To minimize false-positive test results particular attention should be paid to pre-analytical sampling 
conditions. In addition to anatomical imaging by computed tomography (CT) or magnetic resonance imaging, new promising func-
tional imaging modalities of photon emission tomography/CT using with somatostatin analogues such as 68Ga-DOTATATE (68Ga-la-
beled DOTA(0)-Tyr(3)-octreotide) will probably replace 123I-MIBG (iodine-123-metaiodobenzylguanidine) in the near future. As 
nearly half of all pheochromocytoma patients harbor a mutation in one of the 14 tumor susceptibility genes, genetic testing and 
counseling should at least be considered in all patients with a proven tumor. Post-surgical annual follow-up of patients by measure-
ments of plasma or urinary metanephrines should last for at least 10 years for timely detection of recurrent or metastatic disease. Pa-
tients with a high risk for recurrence or metastatic disease (paraganglioma, young age, multiple or large tumors, genetic background) 
should be followed up lifelong.
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INTRODUCTION
Pheochromocytoma and paraganglioma (PPGLs) are rare chro-
maffin cell tumors with a variable prevalence depending on the 
investigated population. In patients with hypertension the preva-
lence of a PPGL is about 0.2% to 0.6% while in patients with an 
incidentally discovered adrenal tumor it is about 3% to 7% [1-
3]. Physicians are apprehensive to miss this tumor because it is 
associated with significant cardiovascular morbidity and cata-
strophic consequences when the diagnosis is overlooked [4-7]. 
Yet, the average delay in the diagnosis is nearly 3 years and it is 
even missed during life in 0.05% to 0.1% of the patients as 
shown by autopsy studies [1]. 
Both PPGLs are chromaffin cell tumors that arise from the 
adrenal medulla (80% to 85%) or from the ganglia of the sym-
pathetic chain in thorax, abdomen, and pelvis (15% to 20%) [8]. 
Paragangliomas located in the head and skull base areas a have 
a parasympathetic origin [9,10]. In terms of biochemical pheno-
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type, adrenal tumors produce epinephrine with a varying amount 
of norepinephrine. Half of all adrenal tumors have an adrenergic 
biochemical phenotype while the other half have a noradrener-
gic phenotype [11]. Extra-adrenal tumors (paragangliomas) 
arising from sympathetic ganglia have a noradrenergic pheno-
type, producing predominantly or exclusively norepinephrine. 
Head and skull base paragangliomas usually do not produce 
catecholamines except for some dopamine and its metabolite 
3-methoxytyramine. PPGLs in childhood have a preponderance 
of extra-adrenal and multifocal tumors and carry an increased 
prevalence of mutations in one of the PPGL susceptibility genes 
[12]. 
The classical signs and symptoms of PPGLs are well known 
but unfortunately are not very specific since they resemble those 
of many other clinical conditions, in particular disorders associ-
ated with increased sympathetic activity. The episodic nature of 
catecholamine secretion is the basis for the paroxysmal nature 
of signs and symptoms, including severe blood pressure fluctua-
tions [1,13,14]. Any paroxysmal signs or symptoms should be a 
compelling clue to consider the presence of a PPGL. Due to the 
combination of rarity and multifaceted presentation of these tu-
mors the diagnosis of PPGLs is not always straightforward. Re-
cently, the indications for screening for PPGLs have been up-
dated (Table 1) [15].
Malignant PPGL is characterized by metastases of chromaffin 
tissue in locations that are normally devoid of chromaffin tissue, 
such as bones, lungs, and liver. The overall prevalence of meta-
static disease among patients with PPGLs is 10% to 15%, but 
may amount to 30% to 40% in the presence of specific risk fac-
tors: young age, genetic background in particular succinate de-
hydrogenase B (SDHB) mutations, large tumor size, dopami-
nergic phenotype, multifocal tumors, and extra-adrenal location 
[16,17].
PRACTICAL APPROACH TO THE 
BIOCHEMICAL DIAGNOSIS
An essential prerequisite prior to ordering biochemical testing 
are a thorough medical history including a family history and 
assessment of factors that may provoke paroxysms such as cer-
tain drugs [1,18]. At physical examination special attention 
should be paid to proper blood pressure measurements. Ambu-
latory 24-hour measurements are not only a more objective as-
sessment of blood pressure but also allow assessment of excep-
tional blood pressure variability. As PPGL may be part of sever-
al hereditary syndromes (e.g., von Hippel-Lindau [VHL] dis-
ease and multiple endocrine neoplasia type 2 [MEN2] syn-
drome), one has to be attentive to other overt or hidden features 
of these syndromes [19-21]. This aspect of the work-up is not 
only very relevant for appropriate interpretation of biochemical 
test results but it also impacts on further more personalized 
management strategy. 
In case of clinical suspicion of a PPGL, the next diagnostic 
step is biochemical testing. Evidence of excess production of 
catecholamines or the O-methylated catecholamine metabolites, 
metanephrines, is in general a condition sine qua non before 
proceeding to more expensive imaging procedures. According 
to the recommendations of the recent Endocrine Society guide-
line, initial biochemical testing for PPGLs should include mea-
surements of plasma free or urinary metanephrines [15]. Plasma 
free metanephrines combined with the dopamine metabolite 
3-methoxytyramine offer a slightly higher sensitivity (99%) 
than that of urinary deconjugated metanephrines (95%). The 
nearly maximal negative predictive value of plasma free meta-
nephrines indicates that a pheochromocytoma or paraganglioma 
can be considered as excluded with a high reliability when the 
test result is within the normal range [22]. This even applies at 
very low pretest probability of disease (0.2% to 0.6%), as is the 
case in asymptomatic hypertensive patients [23]. Exceptions are 
rare patients with biochemically silent tumors who carry an 
SDHB mutation [24]. Elevated levels of 3-methoxytyramine 
may be associated with metastatic disease or can be found in 
patients with neck and skull base paragangliomas. The very 
high diagnostic sensitivity of metanephrines is due to the con-
tinuous diffusion of intratumorally-produced metanephrines 
into the circulation, which contrasts with the episodic secretion 
Table 1. Indications for Biochemical Testing for Pheochromo-
cytoma/Paraganglioma
Signs or symptoms suggesting catecholamine excess, in particular if 
paroxysmal
Unexpected blood pressure response to drugs, surgery, or anesthesia
Unexplained blood pressure variability
Incidentaloma, also in normotensive patients
Difficult to control blood pressure
Previous treatment for pheochromocytoma or paraganglioma
Hereditary risk of pheochromocytoma or paraganglioma in family 
members
Syndromic features relating to a pheochromocytoma-related hereditary 
syndrome
Adapted from Lenders et al. [15]. 
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of the parent catecholamines [25]. In addition, measurements of 
plasma metanephrines result in less false-positive test results 
than those of urinary metanephrines with specificities of 96% 
and 89%, respectively. 
For reliable measurement of metanephrines and interpretation 
of test results, preanalytical conditions need consideration. No 
dietary restrictions are needed for measurements of plasma 
metanephrines except for dietary use of amine rich foods, which 
might result in false-positive test results for 3-methoxytyramine 
[26]. Therefore, blood sampling in the fasting state is advised to 
minimize the risk of false-positive test results. Blood samples 
for measurements of plasma metanephrines (collected in hepa-
rinized tubes or tubes with ethylenediaminetetraacetic acid) 
need to be placed immediately on ice to prevent degradation. If 
samples are assayed within 30 days, storage of plasma at –20°C 
is sufficient [27]. For measurement of urinary metanephrines, 
no special dietary precautions need to be taken and containers 
do not need additives as long as the urine sample is acidified 
(pH 4) before storage [28]. To verify complete 24-hour urine 
collection, simultaneous measurement of urinary creatinine ex-
cretion is useful. 
Several sympathetic stimuli such as stress and upright body 
position may increase plasma metanephrines and this will im-
pact test results. Conversely, taking blood samples in the supine 
position will on average result in 30% lower plasma normeta-
nephrine values as compared to the sitting position. Therefore 
venous blood samples for metanephrines should preferentially 
be taken after supine rest for at least 20 minutes. This will fur-
ther minimize the risk of false-positive test results. A recent sys-
tematic review showed a higher sensitivity of plasma metaneph-
rines if blood samples are taken after supine rest than of samples 
taken in the seated position without rest [29]. If drawing blood 
samples after supine rest is not operational in medical facilities, 
measurement of 24-hour urinary metanephrines is an acceptable 
alternative. 
Before starting biochemical testing, one has to consider false-
positive test results related to the use of specific drugs that can 
cause analytical or pharmacological interference [15]. In case of 
measurements by mass spectrometric methods such as LC-MS/
MS (liquid chromatography with tandem mass spectrometry), 
analytical interference is negligible as compared to high pres-
sure liquid chromatography with electrochemical detection. 
Pharmacodynamic interference is still possible as this is assay 
independent. Typical examples of drugs to consider in case of 
elevated test results are tricyclic antidepressants and sympatho-
mimetic drugs. In cases in which it is not possible to interrupt 
such drugs temporarily, the clinician has a diagnostic dilemma 
and is left with proceding to imaging as the only way out. 
As usual for diagnostic testing in general, one has also to con-
sider the clinical context of the patient, including the pretest 
probability of disease [23]. Increased sympathetic activity is a 
distinctive hallmark of many co-existent conditions. Such co-
morbidities accompanied by strong elevations of sympathoneu-
ral activity are a source of falsely-elevated plasma normeta-
nephrine levels. Typical examples are occult or overt heart fail-
ure or life threatening conditions at the intensive care unit [30]. 
More pronounced elevations of plasma metanephrine can occur 
during severe pain as is the case during cardiac ischemia or hy-
poglycemia. Consequently, in life threatening stressful condi-
tions, as is the case in patients on intensive care units, a reliable 
biochemical diagnosis is not feasible and the next best test to 
rule out PPGL is imaging.
For correct interpretation of test results, one has to consider 
appropriate reference intervals and cut-off values. Preferably 
laboratories should establish or verify their own reference val-
ues. Three important considerations should be noted: first, refer-
ence values should be established from subjects who are sam-
pled after supine rest. This reduces the risk of missing a PPGL. 
Second, the ideal reference population consists of patients who 
were suspected for a PPGL but in whom a PPGL was ruled out. 
Finally, reference values for plasma normetanephrine should be 
adjusted for age while this is not necessary for metanephrine 
and 3-methoxytyramine (Table 2). Although plasma metaneph-
rines and 3-methoxytyramine are slightly higher in males than 
in females, no gender specific cut-off reference values are re-
quired in clinical care.
Paying insufficient attention to how blood is collected and 
how results are interpreted might explain the high rates of mis-
diagnosis, in particular of false-positive test results of up to 
20%, as reported from an academic hypertension clinic [31]. If 
Table 2. Age-Related Upper Cut-off Values for Plasma Meta-
nephrines and 3-Methoxytyramine
Age, yr Normetanephrine, nmol/L
Metanephrine, 
nmol/L
3-Methoxytyramine, 
nmol/L
5–17 0.47 0.45 0.10
18–29 0.58 0.45 0.10
30–39 0.70 0.45 0.10
40–49 0.79 0.45 0.10
50–59 0.87 0.45 0.10
>60 1.05 0.45 0.10
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testing returns positive results for plasma or urinary metaneph-
rines, it is useful to ask yourself the following questions: is 
blood or urine sampling carried out correctly?; does the patient 
use potentially interfering medications?; does the patient suffer 
from comorbidity; or is there another reason for increased sym-
pathetic activity that might explain the test result? 
Finally, for correct interpretation of test results one has to take 
into account pretest probability of disease and the extent of ele-
vation over the upper cut-off value [23]. Increment of plasma 
metanephrines well in excess of 2-fold the upper cut-offs pro-
vides a high level of confidence that the patient has a PPGL 
since such increments are very rare in patients without a PPGL. 
In these patients the diagnostic step is to locate the tumor using 
imaging. In patients with slightly elevated test results (<2-fold 
the upper cut-off), it is difficult to distinguish false-positive 
from true-positive test results. Such patients, in particular when 
the clinical suspicion is low, can be monitored by biochemical 
follow-up to gauge a potentially further increase in plasma 
metanephrines. If clinical suspicion is moderate or high and 
plasma normetanephrine is elevated, a clonidine suppression 
test is useful to exclude the tumor [32].
IMAGING STRATEGIES 
Once a biochemical diagnosis of a catecholamine producing tu-
mor has been established, the next step is to localize the tumor 
by anatomical imaging. Exceptions are critically ill patients in 
emergency situations where imaging has priority over biochem-
ical testing since a reliable and rapid biochemical diagnosis is 
not feasible [30]. Computed tomography (CT) scanning is the 
preferred imaging modality because its outstanding spatial reso-
lution is superior to that of magnetic resonance imaging (MRI). 
MRI is reserved for patients with the following conditions: met-
astatic disease, intracardiac or skull base and neck paraganglio-
mas, postoperative surgical clips, allergy to CT contrast, and in 
those conditions in whom radiation exposure should be limited: 
children, pregnant women, and patients with known germline 
mutations [15]. The abdominal and pelvic areas are the predi-
lection locations for development of most PPGLs (>95%) and 
therefore these locations should be the first to be scanned. 
The diagnostic sensitivity and specificity of CT scanning is 
determined by the location of the tumor and by whether it is re-
current or metastatic disease. The sensitivity for adrenal tumors 
is >90% while that of extra-adrenal, recurrent or metastatic tu-
mors is considerably lower. As CT scanning provides only in-
formation on the presence or absence of a mass, the specificity 
(75% to 80%) is substantially lower than sensitivity. Specific 
imaging characteristics such as density, contrast enhancement 
and contrast wash-out can improve the specificity, but CT still 
falls short to differentiate PPGLs from other adrenal tumors 
[33]. 
MRI imaging with or without gadolinium enhancement is in 
general the second best imaging modality but for extra-adrenal 
and skull base/neck paragangliomas MRI is preferred over CT 
scanning because better spatial resolution [34-36]. Nevertheless, 
several features that impair signal intensity such tumor necrosis 
or hemorrhage limits its diagnostic accuracy. 
A second and complementary imaging step is functional im-
aging, which provides a substantially higher specificity than an-
atomical imaging and is particularly recommended for diagno-
sis of multi-focal or metastatic disease. For this modality specif-
ic ligands targeting either specific cell membrane transporters or 
vesicular catecholamine transport systems are available. De-
pending on the type of ligand single photon emission computed 
tomography (SPECT) is used, as is the case with iodine-
123-metaiodobenzylguanidine (123I-MIBG) and 111In-pentetreo-
tide. Other ligands such as 18F-fluorodeoxyglucose (18F-FDG), 
18F-fluorodihydroxyphenylalanine (18F-FDOPA) and 68Ga-la-
beled DOTA(0)-Tyr(3)-octreotide (68Ga-DOTATATE) are used 
for photon emission tomography (PET), commonly combined 
with CT scanning [37].
The most frequently used ligand for PPGL localization is 123I-
MIBG for scintigraphy and SPECT. The sensitivity of 123I-
MIBG SPECT for detection of adrenal pheochromocytoma is 
excellent (nearly 100%), but is unacceptably low for extra-adre-
nal paragangliomas (56% to 75%) and metastases, particularly 
when associated with underlying succinate dehydrogenase 
(SDHx) mutations (<50%) [38-40]. Apart from this limitation, 
123I-MIBG is very useful to identify patients with metastatic 
PPGL because MIBG avid lesions indicate that these patients 
may benefit from treatment with therapeutic doses of 131I-
MIBG. 
18F-FDOPA PET imaging is recommended for both skull base 
and neck paragangliomas and for non-metastatic PPGLs [41]. 
The diagnostic performance of the newer ligands for PET imag-
ing such as 18F-FDG and 68Ga-DOTATATE depends on specific 
clinical features, such as tumor location, metastases and under-
lying genetic mutation. Sensitivity of 18F-FDG-PET is very high 
for metastatic disease, in particular in patients with SDHB-relat-
ed metastatic PPGL [42]. 68Ga-DOTATATE has a very high and 
selective affinity for tumor-associated somatostatin receptors 
type 2. Preliminary data show that it has an excellent diagnostic 
Lenders JW, et al.
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accuracy in both sporadic and SDHB related metastatic PPGLs 
and the same applies to patients with skull base and neck para-
gangliomas [43-46].
The clinical impact of functional imaging in all PPGL patients 
remains undefended by required large prospective comparative 
clinical studies that take into account the aforementioned spe-
cific clinical features. In addition, solid data on specific ligands 
for functional imaging targeted to specific genotypes are limited 
except for SDHB related PPGLs. Yet, for the time being the 
choice of ligand should be personalized according to such fea-
tures as recently suggested by the Endocrine Society guideline 
[15].
GENETIC TESTING
About 40% of all patients with a PPGL have a germline muta-
tion in one of the 12 susceptibility genes and in 11% to 13% of 
all apparent sporadic cases a germline mutation can be detected 
[15,47-49]. The following genes are involved in hereditary PP-
GLs: neurofibromatosis type 1 (NF1), rearranged during trans-
fection (RET), VHL, transmembrane domain protein 127 
(TMEM127), MYC-associated factor X (MAX), fumarate hy-
dratase (FH), malate dehydrogenase 2 (MDH2), and the succi-
nate dehydrogenase A (SDHA), B (SDHB), C (SDHC), D 
(SDHD) and the succinate dehydrogenase complex assembly 
factor 2 (SDHAF). For most of the recently discovered tumor 
susceptibility genes penetrance has not yet been precisely estab-
lished because of lack of long-term follow-up of non-index cas-
es. However, the known penetrances vary from 2.5% in NF1 to 
>90% in SDHD [50,51].
The genes most frequently mutated are SDHB and VHL while 
MAX, TMEM127, MDH2, SDHAF2, and FH are least frequent-
ly mutated. Mutations of SDHB gene are associated with an in-
creased risk of development of metastatic disease (40% to 60%) 
[52-56] and mutation testing for this gene is particularly indicat-
ed in patients with extra-adrenal tumors (paragangliomas), par-
ticularly when large tumors or when producing 3-methoxy-
tyramine. 
Based on the pathogenic pathways from gene mutation to tu-
mor development two cluster groups can be distinguished 
[21,57]. Cluster 1 tumors develop in patients with germline or 
somatic mutations in VHL, SDHB, SDHD, SDHC, SDHAF2, 
SDHAF2, hypoxia inducible factor 2α (HIF2α), prolyl hydroxy-
lase 2 (PHD2), MDH2, FH genes and involve activation of hy-
poxia-angiogenic pathways. Cluster 2 tumors develop in pa-
tients with mutations in RET, NF1, TMEM127, and MAX and 
involve RAS and kinase signaling pathways. These pathogenic 
differences are associated with differences in biochemical phe-
notypes. Cluster 1 tumors are usually noradrenergic while clus-
ter 2 tumors have an adrenergic phenotype except those with a 
MAX mutation, which are mixed adrenergic/noradrenergic. Tu-
mors with SDHB and SDHD mutation may also produce addi-
tional 3-methoxytyramine. Therefore, among other factors than 
age and tumor location, the biochemical phenotype can guide 
the priority of the genes to be tested [15].
Genetic testing should at least be considered in all patients 
and is strongly indicated in specific patients such as those with a 
positive family history of PPGLs or carriers of tumor suscepti-
bility gene mutations, and those with syndromic features or 
metastatic disease [15]. Other reasons to carry out mutation test-
ing are the presence of risk factors for an underlying mutation: 
young patients, patients with multifocal or bilateral adrenal tu-
mors, and patients with paragangliomas. Identification of a gene 
mutation in these patients might result in earlier detection of 
PPGLs and other neoplasms; thereby, reducing morbidity and 
improving survival. Genetic testing provides also an opportuni-
ty for a more personalized approach so that patient tailored 
management according to risk may result in timely detection of 
disease before metastases will develop. A typical example are 
the patients with SDHB mutations who carry a high risk for de-
veloping metastatic PPGLs. Early identification and close sur-
veillance may be of long term benefit for such patient groups. 
Finally, it should be emphasized that genetic testing should be 
carried out in an accredited laboratory with the availability of 
pre- and posttest counseling.
PREOPERATIVE, SURGICAL, AND 
POSTSURGICAL MANAGEMENT 
Proper presurgical preparation of PPGL patients by a multidis-
ciplinary team is pivotal to guarantee the best possible outcome 
[58,59]. Both improved preoperative medical preparation and 
modern anesthesia and surgical techniques have resulted in a 
currently very low perioperative mortality of less than 1%. 
Medical preparation to prevent and minimize dangerous com-
plications due to massive surges of released catecholamines 
from the tumor is still indispensible in all PPGL patients, in-
cluding asymptomatic and normotensive patients [15,58,60]. 
This rational clinical practice is not evidence based as there are 
no randomised trials. There is however an abundance of case 
reports testifying on the potential catastrophic sequela if ade-
quate preparation is omitted. More importantly, it should be 
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noted that there is no convincing evidence from randomized tri-
als that it is really safe to abandon this longstanding practice.
An essential part of preoperative management is a cardiovas-
cular evaluation, including an electrocardiogram and echocar-
diography. Patients with PPGL may have compromised cardiac 
function such as subclinical left ventricular failure [61]. Proper 
medical treatment of reduced left ventricular function may re-
duce the peroperative cardiovascular risks.
For achieving effective α-blockade, there is no compelling ev-
idence so far that one of the two α-adrenoceptor antagonists, 
phenoxybenzamine or doxazosin, is preferred [62]. There is 
much more experience with the non-competitive α-adrenoceptor 
blocker phenoxybenzamine than with the competitive blocker 
doxazosin. Most centers take 10 to 14 days for this pharmaco-
logical pretreatment to achieve a stabile situation. A randomized 
trial to find out whether any of these drugs is preferred is under 
way. Calcium channel blockers have mainly been used as add-
on drug to α-adrenoceptor blockade although some recent non-
randomised studies found it also effective and safe as monother-
apy [63,64]. A few centers still use the catecholamine-synthesis 
inhibitor α-methylparatyrosine (metyrosine) but there is no evi-
dence that this drug, even as add-on drug, is really necessary for 
presurgical preparation. After installing α-adrenoceptor block-
ade, β-adrenoceptor blockade is part of the armentarium for 
tachycardia and tachyarrhythmias but should only be started af-
ter installment of proper α-adrenoceptor blockade [15]. 
Irrespective of the drug regimen, target sitting blood pressure 
is <130/80 mm Hg with avoiding upright systolic blood pres-
sure of <90 mm Hg. Due to persistent vasodilation because of 
continued α-adrenoceptor blockade, there is a some risk of hy-
potension after tumor removal. To prevent this postsurgical hy-
potension, it is mandatory to prescribe a high-sodium diet and 
high fluid intake during the preparation period although this ad-
vice is not evidence-based [15]. The first 24 hours after tumor 
removal the patient should be strictly monitored to detect and 
treat hypertension, hypotension, or hypoglycemia [58]. In case 
of postsurgical hypotension, one important specific consider-
ation is the possibility of adrenal insufficiency. 
Minimal invasive laparoscopic tumor resection is the standard 
treatment with the posterior retroperitoneal approach as first 
choice in patients with pheochromocytoma [65]. The minimal 
invasive approach applies also to paragangliomas but this de-
pends on location and tumor size. After minimal invasive tumor 
removal, patients experience less blood loss and have a shorter 
stay in hospital as compared to conventional open surgery. Par-
tial adrenalectomy is the preferred option in patients with hered-
itary PPGLs (e.g., MEN2 and VHL syndromes) if technically 
possible [66]. It spares healthy adrenocortical tissue, thus avoid-
ing lifelong steroid replacement therapy in most patients [66]. 
The underlying pathogenetic mutations in these syndromes 
drive however a certain risk of tumor recurrence in the remnant 
tissue after adrenal sparing surgery of 0% to 21% [66-68].
Follow-up of operated patients is essential for long term out-
come for three reasons: surgery might be incomplete, tumors 
might recur or metastases may develop, even after many years. 
There are currently no validated reliable pathology criteria to 
predict that a primary tumor is benign, malignant or will evolve 
into metastatic disease in the future [69]. To ascertain that the 
tumor has been removed completely, measurement of plasma or 
urine metanephrines at 2 to 6 weeks after surgery is recom-
mended. In case of persistently elevated biochemical test re-
sults, additional imaging studies are indicated [70]. Although 
the majority of patients is cured after successful surgery, there is 
a persistent risk of local or metastatic recurrences or a new tu-
Table 3. Key Points for Managing Pheochromocytoma/Para-
ganglioma
Low threshold of consideration of PPGL is key for early diagnosis
Search for clinical clues that require biochemical testing for PPGL
Consider syndromic features related to hereditary pheochromocytoma 
syndrome
Use as initial biochemical test: plasma or urinary metanephrines
Blood sampling: preferably after at least 20 minutes of supine rest
Consider proper pre-analytical test conditions, including use of inter-
fering drugs
Check creatinine excretion for completeness of 24-hour urine sampling
Preferred assay method: use LC-MS/MS or HPLC-ED
Use as first imaging test: CT scan; MRI reserved for specific indica-
tions
Choice of functional imaging based on location and genetic back-
ground
Consider genetic testing in all patients in the framework of genetic 
counselling
Preoperative evaluation and medical preparation using α-adrenoceptor 
blockade are essential
Annual postsurgical follow-up for at least 10 years is mandatory for all 
patients 
Follow-up should be lifelong in patients with an increased risk for re-
currence
PPGL, pheochromocytoma or paraganglioma; LC-MS/MS, liquid chro-
matography with tandem mass spectrometry; HPLC-ED, high pressure 
liquid chromatography with electrochemical detection; CT, computed 
tomography; MRI, magnetic resonance imaging.
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mor of 5% during 5 years follow-up [71] in patients with appar-
ent complete resection of the tumor. Risk of recurrent disease is 
higher in young patients (<20 years), in those with syndromic 
presentations, in those with paragangliomas and in patients with 
large tumors. However, there is no ‘safe’ tumor size below 
which the risk is zero. A recent guideline recommended there-
fore to maintain postsurgical follow-up in all operated patients 
for at least 10 years. In patients at high-risk for recurrent disease 
such as the young ones, those who with a germline mutation, 
and those with an extra-adrenal or large tumor, follow-up should 
be continued lifelong [70]. Annual follow-up should include a 
medical history, proper blood pressure measurements and mea-
surements of plasma or urinary fractionated metanephrines. The 
main recommendations for modern management of PPGLs are 
summarized in Table 3.
CONCLUSIONS
The last three decades have shown an enormous progress in the 
biochemical and functional diagnosis of PPGLs. In addition, the 
improved knowledge of the genetic background has not only 
contributed to a better understanding of the pathophysiological 
pathways involved but has also positively impacted clinical 
care. However, as a timely diagnosis and proper treatment can 
prevent potentially catastrophic complications, an early consid-
eration of the presence of such tumor in patients is the key to 
provide the optimal outcome for patients and relatives. 
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